{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T17:21:36Z","timestamp":1769188896250,"version":"3.49.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2020,7,10]],"date-time":"2020-07-10T00:00:00Z","timestamp":1594339200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,7,10]],"date-time":"2020-07-10T00:00:00Z","timestamp":1594339200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Neurol Belg"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1007\/s13760-020-01430-2","type":"journal-article","created":{"date-parts":[[2020,7,10]],"date-time":"2020-07-10T09:03:43Z","timestamp":1594371823000},"page":"1591-1597","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Evaluation of clinical outcome and safety profile of edaravone in treatment of amyotrophic lateral sclerosis: a 72-week single-center experience"],"prefix":"10.1007","volume":"121","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9788-7044","authenticated-orcid":false,"given":"Ismail Ibrahim","family":"Ismail","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fathi","family":"Massoud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Walaa Ahmed","family":"Kamel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jasem Youssef","family":"Al-Hashel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,7,10]]},"reference":[{"issue":"9769","key":"1430_CR1","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1016\/S0140-6736(10)61156-7","volume":"377","author":"MC Kiernan","year":"2011","unstructured":"Kiernan MC, Vucic S, Cheah BC, Turner MR, Eisen A, Hardiman O et al (2011) Amyotrophic lateral sclerosis. Lancet 377(9769):942\u2013955","journal-title":"Lancet"},{"issue":"5","key":"1430_CR2","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1136\/jnnp.2009.188151","volume":"9","author":"K Talbot","year":"2009","unstructured":"Talbot K (2009) Motor neuron disease: the bare essentials. Pract Neurol 9(5):303\u2013309","journal-title":"Pract Neurol"},{"key":"1430_CR3","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1080\/146608202760196048","volume":"3","author":"MR Cookson","year":"2002","unstructured":"Cookson MR, Menzies FM, Manning P et al (2002) Cu\/Zn superoxide dismutase (SOD1) mutations associated with familial amyotrophic lateral sclerosis (ALS) affect cellular free radical release in the presence of oxidative stress. Amyotroph Lateral Scler Other Motor Neuron Disord 3:75\u201385","journal-title":"Amyotroph Lateral Scler Other Motor Neuron Disord"},{"issue":"3\u20134","key":"1430_CR4","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1159\/000089620","volume":"2","author":"P Van Cutsem","year":"2005","unstructured":"Van Cutsem P, Dewil M, Robberecht W, Van Den Bosch L (2005) Excitotoxicity and amyotrophic lateral sclerosis. Neurodegener Dis 2(3\u20134):147\u2013159","journal-title":"Neurodegener Dis"},{"issue":"2","key":"1430_CR5","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1002\/med.21528","volume":"39","author":"MK Jaiswal","year":"2019","unstructured":"Jaiswal MK (2019) Riluzole and edaravone: a tale of two amyotrophic lateral sclerosis drugs. Med Res Rev 39(2):733\u2013748","journal-title":"Med Res Rev"},{"key":"1430_CR6","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1080\/17482960600881870","volume":"7","author":"H Yoshino","year":"2006","unstructured":"Yoshino H, Kimura A (2006) Investigation of the therapeutic effects of edaravone, a free radical scavenger, on amyotrophic lateral sclerosis (phase II study). Amyotroph Lateral Scler 7:241\u2013245","journal-title":"Amyotroph Lateral Scler"},{"key":"1430_CR7","doi-asserted-by":"publisher","first-page":"610","DOI":"10.3109\/21678421.2014.959024","volume":"15","author":"K Abe","year":"2014","unstructured":"Abe K, Itoyama Y, Sobue G et al (2014) Confirmatory double-blind, parallel-group, placebocontrolled study of efficacy and safety of edaravone (MCI-186) in amyotrophic lateral sclerosis patients. Amyotroph Lateral Scler Frontotemporal Degener 15:610\u2013617","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"},{"key":"1430_CR8","first-page":"3","volume":"86","author":"M Tanaka","year":"2015","unstructured":"Tanaka M, Sakata T, Palumbo J, Akimoto M (2015) A 24-week, phase III, double-blind, parallel-group study of edaravone (MCI-186) for treatment of amyotrophic lateral sclerosis (ALS). Neurology 86:3\u2013189","journal-title":"Neurology"},{"issue":"2","key":"1430_CR9","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1002\/mus.26740","volume":"61","author":"J Shefner","year":"2020","unstructured":"Shefner J, Heiman-Patterson T, Pioro EP, Wiedau-Pazos M, Liu S, Zhang J et al (2020) Long-term edaravone efficacy in amyotrophic lateral sclerosis: post-hoc analyses of Study 19 (MCI186-19). Muscle Nerve 61(2):218\u2013221","journal-title":"Muscle Nerve"},{"issue":"5","key":"1430_CR10","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1080\/146608200300079536","volume":"1","author":"BR Brooks","year":"2000","unstructured":"Brooks BR, Miller RG, Swash M, Munsat TL (2000) El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 1(5):293\u2013299","journal-title":"Amyotroph Lateral Scler Other Motor Neuron Disord"},{"issue":"1\u20132","key":"1430_CR11","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/S0022-510X(99)00210-5","volume":"169","author":"JM Cedarbaum","year":"1999","unstructured":"Cedarbaum JM, Stambler N, Malta E, Fuller C, Hilt D, Thurmond B et al (1999) The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. J Neurol Sci 169(1\u20132):13\u201321","journal-title":"J Neurol Sci"},{"issue":"7","key":"1430_CR12","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/S1474-4422(17)30115-1","volume":"16","author":"K Abe","year":"2017","unstructured":"Abe K, Aoki M, Tsuji S, Itoyama Y, Sobue G, Togo M et al (2017) Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 16(7):505\u2013512","journal-title":"Lancet Neurol"},{"key":"1430_CR13","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.jns.2019.06.006","volume":"404","author":"A Fortuna","year":"2019","unstructured":"Fortuna A, Gizzi M, Bello L, Martinelli I, Bertolin C, Pegoraro E, Edaravone Study Group et al (2019) Safety and efficacy of edaravone compared to historical controls in patients with amyotrophic lateral sclerosis from North-Eastern Italy. J Neurol Sci 404:47\u201351","journal-title":"J Neurol Sci"},{"key":"1430_CR14","first-page":"1","volume":"11","author":"JS Mora","year":"2019","unstructured":"Mora JS, Genge A, Chio A, Estol CJ, Chaverri D, Hern\u00e1ndez M et al (2019) Masitinib as an add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: a randomized clinical trial. Amyotroph Lateral Scler Frontotemporal Degener 11:1\u201310","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"},{"key":"1430_CR15","doi-asserted-by":"publisher","DOI":"10.1080\/21678421.2019.1599955","author":"JM Palumbo","year":"2019","unstructured":"Palumbo JM, Hubble J, Apple S, Takei K, Tsuda K, Liu S et al (2019) Post-hoc analyses of the edaravone clinical trials study 16 and study 19: a step toward more efficient clinical trial designs in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. https:\/\/doi.org\/10.1080\/21678421.2019.1599955","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"},{"key":"1430_CR16","doi-asserted-by":"publisher","first-page":"83","DOI":"10.2217\/nmt.13.74","volume":"4","author":"S Pinto","year":"2014","unstructured":"Pinto S, de Carvalho M (2014) Breathing new life into treatment advances for respiratory failure in amyotrophic lateral sclerosis patients. Neurodegen Dis Manag 4:83\u2013102. https:\/\/doi.org\/10.2217\/nmt.13.74","journal-title":"Neurodegen Dis Manag"},{"key":"1430_CR17","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1136\/jnnp.2005.072660","volume":"77","author":"A Czaplinski","year":"2006","unstructured":"Czaplinski A, Yen AA, Appel SH (2006) Forced vital capacity (FVC) as an indicator of survival and disease progression in an ALS clinic population. J Neurol Neurosurg Psychiatry 77:390\u2013392","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1430_CR18","doi-asserted-by":"publisher","first-page":"109","DOI":"10.3389\/fneur.2019.00109","volume":"10","author":"S Pinto","year":"2019","unstructured":"Pinto S, de Carvalho M (2019) SVC is a marker of respiratory decline function, similar to FVC, in patients with ALS. Front Neurol 10:109. https:\/\/doi.org\/10.3389\/fneur.2019.00109","journal-title":"Front Neurol"},{"issue":"9","key":"1430_CR19","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1001\/jamaneurol.2014.1129","volume":"71","author":"A Chi\u00f2","year":"2014","unstructured":"Chi\u00f2 A, Calvo A, Bovio G et al (2014) Amyotrophic lateral sclerosis outcome measures and the role of albumin and creatinine: a population-based study. JAMA Neurol 71(9):1134\u20131142. https:\/\/doi.org\/10.1001\/jamaneurol.2014.1129","journal-title":"JAMA Neurol"},{"issue":"1","key":"1430_CR20","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/s10072-019-04055-3","volume":"41","author":"JM Park","year":"2020","unstructured":"Park JM, Kim SY, Park D, Park JS (2020) Effect of edaravone therapy in Korean amyotrophic lateral sclerosis (ALS) patients. Neurol Sci 41(1):119\u2013123","journal-title":"Neurol Sci"}],"container-title":["Acta Neurologica Belgica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13760-020-01430-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13760-020-01430-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13760-020-01430-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,12]],"date-time":"2021-11-12T16:33:37Z","timestamp":1636734817000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13760-020-01430-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,10]]},"references-count":20,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1430"],"URL":"https:\/\/doi.org\/10.1007\/s13760-020-01430-2","relation":{},"ISSN":["0300-9009","2240-2993"],"issn-type":[{"value":"0300-9009","type":"print"},{"value":"2240-2993","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,10]]},"assertion":[{"value":"16 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"None of the authors has any conflict of interest to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"We confirm that we have read the Journal\u2019s position on issues involved in ethical publication and affirm that this report is consistent with those guidelines.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical publication statement"}}]}}